Advertisement: TTP Killer 50
21 January, 2021 - 20:29 By Tony Quested

New CRO from China joins Repositive cancer model network

Fast-growing Chinese business IDMO is joining Cambridge-based Repositive’s  global network of CRO partners. 

IDMO has more than six years of experience in developing mouse PDX models for cancer research and personalised medicine. 

With this new partnership, Repositive is expanding its global reach and model selection to support more biopharma customers in sourcing the right preclinical cancer models for their oncology drug development programmes.

Repositive’s core offering is a specialist and confidential concierge service, namely the Cancer Models Scout (CMS), which provides tailored model recommendations to cancer researchers based on a search across Repositive’s extended global network of 20,000+ preclinical models. 

Customers receive a data-rich report of all identified matching models within 2-4 weeks of submitting a query, which helps to significantly speed up the sourcing of cancer models for preclinical oncology studies. 

Repositive has a growing track record of saving researchers months to years by connecting them to the right cancer models in a much faster timeframe.

CEO Catherine McDermott said: “We are excited to be adding another CRO to our list of partners this early in the year. Following our recent pivot towards the Cancer Model Scout offering, we are committed to ensuring the continued growth of our CRO network so that we can optimise our model search capabilities for all our biopharma customers.”

Siying Peng, CEO of IDMO, added: “We are very happy to be partnering with Repositive and sharing our unique collection of 7000+ PDX models with a wider audience. 

“Each of our models comes with a complete set of clinical data, and can be used for various applications, including the study of tumorigenesis mechanisms and for in-depth efficacy assessments of anti-tumour drugs. 

“Our biobank of models is growing constantly, with over 200 PDX models added every month.”

Repositive also provide unlimited access to its Cancer Models Platform as part of the CMS service, which displays curated and standardised metadata from over 8,000 preclinical cancer models, made available for biopharma researchers to browse anytime, anywhere.

The platform provides the option of filtering content by primary site, model type, subtype, gene mutation, variant, treatment and treatment response. This helps to lessen the workload for researchers and in-house bioinformatics teams supporting in vivo oncology researchers by providing an easy-access interface through which additional model queries can be performed. 

Newsletter Subscription

Stay informed of the latest news and features